Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42256 | 0.97 | TSHR (0.36) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL1171122 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL341962 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL1119343 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL8981788 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL5974062 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2791336 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL6861198 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL768330 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL7629526 | 0.95 | TSHR (0.35) | TSHRALDH1A1KMT2ACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090972-A1 | Oligomers and Polymers Containing Sulfinate Groups, and Methods for Producing the Same | KERRES JOCHEN | 2008-04-17 | — | — | US | claimed |
| US-20050165172-A1 | Oligomers and polymers containing sulfinate groups, and method for producing the same | KERRES JOCHEN (DE) | 2005-07-28 | — | — | US | claimed |
| US-6521222-B1 | Topical cosmetics such as strontium 2,4-pentanedionate applied to keratin fibers, nails and/or mucous membranes for injuries, eczema, ulcers, fibrosis, psoriasis, pruritus, dermatitis, warts and for aging or wrinkle resistance | SOCIETE L'OREAL S.A. (FR) | 2003-02-18 | — | — | US | claimed |
| US-5314866-A | Formation of superconducting Bi-Sr-Ca-Cu-O films by organometallic chemical vapor deposition | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1994-05-24 | — | — | US | claimed |
| CN-107204291-B | Method for manufacturing field effect transistor, memory element, display device, and system | 株式会社理光 | 2021-01-12 | — | — | CN | disclosed |
| US-9908819-B1 | Printing method for production a ceramic green body | WZR ceramic solutions GmbH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-20080090972-A1 | Oligomers and Polymers Containing Sulfinate Groups, and Methods for Producing the Same | KERRES JOCHEN | 2008-04-17 | — | — | US | disclosed |
| US-7288599-B2 | Oligomers and polymers containing sulfinate groups, and method for producing the same | KERRES JOCHEN | 2007-10-30 | — | — | US | disclosed |
| US-20050165172-A1 | Oligomers and polymers containing sulfinate groups, and method for producing the same | KERRES JOCHEN (DE) | 2005-07-28 | — | — | US | disclosed |
| US-20030143252-A1 | Inorganic/organic complexes for reducing skin irritation | PHILIPPE MICHEL (FR) | 2003-07-31 | — | — | US | disclosed |
| US-6521222-B1 | Topical cosmetics such as strontium 2,4-pentanedionate applied to keratin fibers, nails and/or mucous membranes for injuries, eczema, ulcers, fibrosis, psoriasis, pruritus, dermatitis, warts and for aging or wrinkle resistance | SOCIETE L'OREAL S.A. (FR) | 2003-02-18 | — | — | US | disclosed |
| US-6211096-B1 | Tunable dielectric constant oxide and method of manufacture | LSI LOGIC CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0663001-B1 | FUEL ADDITIVES | ASS OCTEL (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998043286-A1 | TUNABLE DIELECTRIC CONSTANT OXIDE AND METHOD OF MANUFACTURE | SYMBIOS, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5593464-A | POLLUTION CONTROL | THE ASSOCIATED OCTEL COMPANY LIMITED (GB) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143252-A1 | Inorganic/organic complexes for reducing skin irritation | DEK, CUTA, TRPV2 | TSHR 4207/4885ALDH1A1 1515/4885KMT2A 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.